KR102342695B1 - Cosmetic composition for skin soothing - Google Patents

Abstract

Disclosed is a cosmetic composition for skin soothing in the present application. The cosmetic composition according to one embodiment comprises a Houttuynia cordata extract and a Melaleuca alternifolia extract as active ingredients. It is possible to have excellent effects in soothing skin heat, soothing external stimuli, improving redness, and confining pores by mixing the Houttuynia cordata extract and the Melaleuca alternifolia extract in an appropriate amount.

Description

Cosmetic composition for skin soothing {Cosmetic composition for skin soothing}

The following examples relate to a cosmetic composition for soothing the skin, and more specifically, to a cosmetic composition comprising an extract of yakmomil extract and a tea tree extract as active ingredients.

Modern people living in the city are exposed to factors such as pollution that irritates the skin, ultraviolet rays, or air conditioning in an enclosed space. These factors can also cause redness, itching, tightness and/or swelling. Often, irritated skin shows a mild inflammatory response.

Therefore, it is necessary to develop a skin soothing cosmetic composition containing a natural material extract that can exhibit an excellent skin improvement effect while improving skin safety and stability when containing cosmetics by reducing skin irritation caused by chemicals. .

According to Registered Patent No. 10-1868050, there is disclosed a method of fermentation of ssam using medicinal flowers and a composition for external application for skin using the same. The above document discloses antibacterial action, immune enhancing action, anti-inflammatory action, etc. of Yakmomil, but only discloses it as one component of the complex extract, and relates to the effect on anti-aging. Publication No. 10-2015-0116504 discloses a cosmetic composition comprising a tea tree extract, but only discloses a specific use in combination with salt.

In this situation, the present inventors have completed the present invention by discovering that by blending the medicinal buckwheat extract and tea tree extract in appropriate amounts, it can have excellent effects in soothing skin heat, soothing external stimuli, improving redness, and reducing pore size.

1. Korea Patent Publication No. 10-1868050 2. Korean Patent Publication No. 10-2015-0116504

Examples have a problem to disclose a cosmetic composition for soothing the skin. Specifically, it is intended to develop a cosmetic composition that has excellent effects on skin heat soothing, external stimulation soothing, redness improvement, pore size reduction, and non-irritating to the skin. Furthermore, there is a challenge in finding a suitable composition for a cream formulation.

As an aspect for solving the above problems, the present application provides a cosmetic composition for skin soothing, comprising, as an active ingredient, a yakmomil extract and a tea tree extract. The yakmomil extract has a concentration of 60 to 80% (w/w), the tea tree extract has a concentration of 8.0 to 12.0% (w/w), and the yakmomil extract and the tea tree extract are 1: 0.8 to It may have a weight ratio of 1.2.

According to one embodiment of the present application, the cosmetic composition has the form of a cream formulation,

The cream formulation is from the group consisting of panthenol, sodium hyaluronate, sodium hyaluronate crosspolymer, hydrolyzed hyaluronic acid, hyaluronic acid, and hydrolyzed sodium hyaluronate. a moisturizing agent of choice;

containing at least one oil selected from the group consisting of caprylic/capric triglyceride, ethylhexyl palmitate, and isododecane;

It may include one or more polymers selected from acrylate/C10-30 alkyl acrylate crosspolymer, ammonium acryloyldimethyltaurate/vpicopolymer, and glyceryl acrylate/acrylic acid copolymer.

According to another embodiment of the present application, the cosmetic composition comprises 0.08 to 0.12% by weight of the yakmomil extract, 0.08 to 0.12% by weight of the tea tree extract, and 0.024 to 0.036% by weight of the panthenol, and the caprylic / Capric triglyceride 1.6 to 2.4 wt%, the ethylhexyl palmitate 1.6 to 2.4 wt%, and the isododecane 0.8 to 1.2 wt%, the acrylate / C10-30 alkyl acrylate crosspolymer 0.4 to 0.6% by weight, 0.4 to 0.6% by weight of the ammonium acryloyldimethyltaurate/vpicopolymer, and 0.16 to 0.24% by weight of the glyceryl acrylate/acrylic acid copolymer.

According to another embodiment of the present application, the cosmetic composition comprises 0.08 to 0.12 wt% of butylene glycol, caprylyl glycol, and pentylene glycol, and 0.008 to 0.012 wt% of arginine, 1,2-hexanediol 1.6 to 2.4% by weight, ethylhexylglycerin 2.4 to 3.6% by weight, polyglyceryl-3methylglucose distearate 0.4 to 0.6% by weight, disodium It may contain 0.08 to 1.2 wt% of DTA and dipotassium glycyrrhizate.

According to another embodiment of the present application, the yakmomil extract and tea tree extract may be provided by filtration after extraction in water at 20 to 60° C. for 1 to 3 days.

An apparatus according to an embodiment may be controlled by a computer program stored in a medium to execute the method of any one of the above-described methods in combination with hardware.

Examples have excellent effects in soothing skin heat, soothing external stimuli, improving redness, and reducing pore size. Furthermore, there is no irritation even when applied to sensitive skin.

Hereinafter, embodiments will be described in detail with reference to the accompanying drawings. However, since various changes may be made to the embodiments, the scope of the patent application is not limited or limited by these embodiments. It should be understood that all modifications, equivalents and substitutes for the embodiments are included in the scope of the rights.

Specific structural or functional descriptions of the embodiments are disclosed for purposes of illustration only, and may be changed and implemented in various forms. Accordingly, the embodiments are not limited to the specific disclosure form, and the scope of the present specification includes changes, equivalents, or substitutes included in the technical spirit.

Although terms such as first or second may be used to describe various elements, these terms should be interpreted only for the purpose of distinguishing one element from another. For example, a first component may be termed a second component, and similarly, a second component may also be termed a first component.

When a component is referred to as being “connected to” another component, it may be directly connected or connected to the other component, but it should be understood that another component may exist in between.

Terms used in the examples are used for the purpose of description only, and should not be construed as limiting. The singular expression includes the plural expression unless the context clearly dictates otherwise. In this specification, terms such as "comprise" or "have" are intended to designate that a feature, number, step, operation, component, part, or a combination thereof described in the specification exists, but one or more other features It should be understood that this does not preclude the existence or addition of numbers, steps, operations, components, parts, or combinations thereof.

Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiment belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and should not be interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application. does not

Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described below in detail in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in a variety of different forms, and only these embodiments allow the disclosure of the present invention to be complete, and common knowledge in the technical field to which the present invention belongs It is provided to fully inform the possessor of the scope of the invention, and the present invention is only defined by the scope of the claims.

In the embodiments of the present invention, unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. have meaning Terms such as those defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in an embodiment of the present invention, an ideal or excessively formal meaning is not interpreted as

The shapes, sizes, proportions, angles, numbers, etc. disclosed in the drawings for explaining the embodiments of the present invention are illustrative and the present invention is not limited to the illustrated matters. In addition, in describing the present invention, if it is determined that a detailed description of a related known technology may unnecessarily obscure the gist of the present invention, the detailed description thereof will be omitted. When 'including', 'having', 'consisting', etc. mentioned in this specification are used, other parts may be added unless 'only' is used. When a component is expressed in the singular, cases including the plural are included unless otherwise explicitly stated.

In interpreting the components, it is construed as including an error range even if there is no separate explicit description.

The size and thickness of each component shown in the drawings are illustrated for convenience of description, and the present invention is not necessarily limited to the size and thickness of the illustrated component.

Each feature of the various embodiments of the present invention may be partially or wholly combined or combined with each other, and as those skilled in the art will fully understand, technically various interlocking and driving are possible, and each embodiment may be implemented independently of each other, It may be possible to implement together in a related relationship.

A cosmetic composition for skin soothing according to an embodiment of the present application will be described.

The cosmetic composition for skin soothing according to an embodiment of the present application includes an extract of yakmomil extract and a tea tree extract as active ingredients.

Houttuynia cordata THUNB. It is also called eoseongcho because the leaves and stems smell like fishy meat. It has several names, such as Chinese herbal medicine, japchae, and sipyak. Yak buckwheat is rich in Quercitrin, a component that removes toxins from the skin, and helps to clear pores and alleviate skin troubles through anti-inflammatory action. It has been known since ancient times as an excellent detoxifying herb.

Tea tree ( Melaleuca alternifolia ) is an evergreen arboreous belonging to the genus Melaleuca alternifolia. This swampy plant is native to Australia and is native to New South Wales. It grows up to about 6m in height and has strong vitality to grow well even if the stem is cut. Tea tree extract has a natural disinfectant function, so it has been used as a natural antibacterial disinfectant by Aboriginal Australians for thousands of years, and was also used to treat wounds by soldiers during World War II as a skin wound treatment.

According to the examples of the present application, it was confirmed that the cosmetic composition of the present invention exhibits a synergistic effect on skin soothing and pore care when the herbal extract and tea tree extract are blended in a specific ratio. Tea tree extract may cause skin irritation when used in a high content, but when combined with yak buckwheat extract in a certain ratio, the skin soothing effect may be excellent. Specifically, the yakmomil extract may have a concentration of 60 to 80% (w/w), and the tea tree extract may have a concentration of 8.0 to 12.0% (w/w). In addition, the yakmomil extract and the tea tree extract may have a weight ratio of 1: 0.8 to 1.2.

According to one embodiment of the present invention, the yakmomil extract and tea tree extract may be provided by filtration after extraction in water at 20 to 60° C. for 1 to 3 days.

It is not limited to the cosmetic composition presented in one embodiment of the present application, and may include additional ingredients such as cosmetic ingredients and pharmaceutically active ingredients other than the active ingredient. Non-limiting examples of these additional ingredients are set forth in the specification below.

The CTFA International Cosmetic Ingredient (2004 and 2008) describes a wide variety of non-limiting cosmetic ingredients that can be used in the context of the present invention. Examples of these ingredient classifications include the following ingredients: fragrances (artificial and natural), dyes and color ingredients (eg Blue 1, blue) Blue 1 Lake, Red 40 (Red 40), titanium dioxide, D&C blue no. 4 (D&C blue no. 4), D&C green no. 5 (D&C green no. 5), D&C orange No. 4 (D&C orange no. 4), D&C red No. 17 (D&C red no. 17), D&C red No. 33 (D&C red no. 33), D&C purple No. 2 (D&C violet no. 2), D&C yellow no. 10, and D&C yellow no. 11), adsorbents, lubricants, solvents, moisturizers (such as For example, emollients, humectants, film formers, occlusive agents, and agents that affect the skin's natural moisturizing mechanism), water repellants ( water-repellants, UV absorbers (paraaminobenzoic acid (“PABA”) and corresponding PABA derivatives, titanium dioxide, zinc oxide) physical and chemical absorbents such as , etc.), essential oils, vitamins (eg, A, B, C, D, E, and K), trace metals (eg, zinc ), calcium and selenium), anti-irritants (eg, steroids ds) and nonsteroidal anti-inflammatories, botanical extracts (eg aloe vera, chamomile, cucumber extract, ginkgo biloba) ), ginseng, and rosemary), anti-microbial agents, antioxidants (e.g., BHT and tocopherol), chelating agents (e.g. For example, disodium EDTA (disodium EDTA) and tetrasodium EDTA (tetrasodium EDTA)), preservatives (e.g. methylparaben and propylparaben), pH adjusters (e.g. For example, sodium hydroxide and citric acid), absorbents (e.g., aluminum starch octenylsuccinate, kaolin, corn starch) , oat starch, cyclodextrin, talc, and zeolite), skin bleaching and lightening agents (e.g., hydroquinone, and niacinamide lactate), humectants (e.g., sorbitol, urea, and manitol), exfoliants, waterproofing agents (e.g., sorbitol, urea, and manitol) For example, magnesium/aluminum hydroxide stearate), skin conditioning agents (co nditioning agents) (e.g., aloe extracts, allantoin, bisabolol, ceramides, dimethicone, hyaluronic acid, and dipotassium glycyrrhizin) Zate (dipotassium glycyrrhizate). Non-limiting examples of some of these ingredients are provided in the specification below.

UV absorbers may be used in combinations of the compositions of the present invention. Includes chemical and physical sunscreens. Non-limiting examples of chemical sunblocks that may be used include para-aminobenzoic acid (PABA), PABA esters (glyceryl PABA (glyceryl PABA), amyldimethyl PABA (amyldimethyl PABA), and octyldimethyl PABA)), butyl PABA, ethyl PABA, ethyl dihydroxypropyl PABA, benzophenones (oxybenzone, sulisobenzone, benzo benzophenone, and benzophenone-1 via 12), cinnamates (octyl methoxycinnamate, isoamyl p-methoxycinnamate, jade octylmethoxy cinnamate, cinoxate, diisopropyl methyl cinnamate, DEA-methoxycinnamate, ethyl diisopropylcinnamate, Glyceryl octanoate dimethoxycinnamate and ethyl methoxycinnamate), cinnamate esters, salicylates (homomethyl salicylate, benzylsalicylic acid) benzyl salicylate, glycol salicylate, isopropylbenzyl salicylate, etc.), anthranilates, ethyl urocanate, homos alate), octisalate, dibenzoylmethane derivatives (eg avobenzone), octocrylene, octyl triazone, digalloy triol digalloy trioleate, glyceryl aminobenzoate, dihydroxyacetone and lawson, ethylhexyl triazone, dioctyl butamido triazone, Benzylidene malonate polysiloxane, terephthalylidene dicamphor sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, diethylamino hydroxybenzol (diethylamino hydroxybenzoyl hexyl benzoate), bis diethylamino hydroxybenzoyl benzoate, bis benzoxazolylphenyl ethylhexylimino triazine (bis benzoxazoylphenyl ethylhexylimino triazine), drometrizole trisiloxane , methylene bis-benzotriazolyl tetramethylbutylphenol (methylene bis-benzotriazolyl tetramethylbutyiphenol), and bis-ethylhexyloxyphenol methoxyphenyltriazine, 4-methylbenzylidenecamphor, and isopentyl 4-methoxycinnamat e) is included. Non-limiting examples of physical sunblocks include kaolin, talc, petrolatum and metal oxides (eg, titanium dioxide and zinc oxide). )) is included.

A moisturizing agent may be used in the cosmetic composition of the present invention, and as non-limiting examples, amino acids, chondroitin sulfate, diglycerin, erythritol, fructose, glucose ), glycerin, glycerol polymers, glycol, 1,2,6-hexanetriol (1,2,6-hexanetriol), honey, hyaluronic acid ( hyaluronic acid, hydrogenated honey, hydrogenated starch hydrolysate, inositol, lactitol, maltitol, maltose, mannitol, natural natural moisturizing factor, PEG-15 butanediol, polyglyceryl sorbitol, salts of pyrrolidone carboxylic acid, potassium PCA, propylene Glycol (propylene glycol), sodium glucuronate, sodium PCA (sodium PCA), sorbitol (sorbitol), sucrose (sucrose), trehalose (trehalose), urea (urea), and xylitol ( xylitol).

Other embodiments acetylating a lanolin (lanolin), acetylation of a lanolin alcohol (lanolin alcohol), alanine (alanine), algae extract (algae extract), aloe Bar-Baden sheath (aloe barbadensis), aloe-Barr Baden sheath (aloe -barbadensis extract, aloe barbadensis gel, althea officinalis extract, apricot ( prunus armeniaca ) kernel oil, arginine ), arginine aspartate, arnica montana extract, aspartic acid, avocado ( persea gratissima ) oil, barrier sphingolipids, butyl alcohol alcohol), beeswax, behenyl alcohol, beta-sitosterol, birch ( betula alba ) bark extract, borage ) ( borago officinalis ) extract, butcherbroom ruscus aculeatus extract, butylene glycol, calendula officinalis ( calendula officinalis ) extract, calendula officinalis oil, candelilla ( euphorbia cerifera ) wax, canola oil, caprylic/capric triglyceride, cardamon ( elettaria cardamo) mum )) oil, carnauba ( copernicia cerifera ) wax, carrot ( daucus carota sativa ) oil, castor ( ricinus commune ( ) ricinus communis )) oil, ceramides, ceresin, ceteareth-5, ceteareth-12, ceteareth-20, cetearyl octa cetearyl octanoate, ceteth-20, ceteth-24, cetyl acetate, cetyl octanoate, cetyl palmitate , chamomile ( anthemis nobilis ) oil, cholesterol, cholesterol esters, cholesterol hydroxystearate, citric acid, clay ( salvia sclarea ) oil, cocoa ( theobroma cacao ) butter, coco-caprylate/caprate, coconut ( cocos nucifera) )) oil, collagen, collagen amino acids, corn ( zea mays ) oil, fatty acids, decyl oleate, dimethicone copolyol , thimethiconol, dioctyl adipate, dioctyl succinate, dipentaerythritylhexaprylate / hexafrate (dipentaerythrityl hexacaprylate/hexacaprate), DNA, erythritol, ethoxydiglycol, ethyl linoleate, eucalyptus globulus oil, evening primrose Biennis ( oenothera biennis ) oil, fatty acids, geranium maculatum oil, glucosamine, glucose glutamate, glutamic acid, glycereth-26, glycerin (glycerin), glycerol, glyceryl distearate, glyceryl hydroxystearate, glyceryl laurate, glyceryl linoleate, glyceryl glyceryl myristate, glyceryl oleate, glyceryl stearate, glyceryl stearate SE, glycine, glycol stearate , glycol stearate SE, glycosaminoglycans, grape ( vitis vinifera ) seed oil, hazel ( corylus americana ) nut (nut) oil, hazel ( corylus avellana ) nut oil, hexylene glycol, hyaluronic acid, hybrid safflower ( carthamus tinctorius ) oil, hydrogenated castor oil, hydrogenated coco-glycerides, hydrogenated coconut oil, hydrogenated lanolin, hydrogenated lecithin , hydrogenated palm glyceride, hydrogenated palm kernel oil, hydrogenated soybean oil, hydrogenated tallow glyceride, hydrogenated vegetable oil, hydrolyzed collagen, hydrolyzed elastin ( elastin), hydrolyzed glycosaminoglycans, hydrolyzed keratin, hydrolyzed soy protein, hydroxylated lanolin, hydroxyproline, iso cetyl stearate, isocetyl stearoyl stearate, isodecyl oleate, isopropyl isostearate, isopropyl lanolate, iso Propyl myristate, isopropyl palmitate, isopropyl stearate, isostearamide DEA, isostearic acid, isostearyl lactate ( isostearyl lactate), isostearyl neopentanoate, jasmine ( jasminum officinale ) oil, jojoba (( buxus chinensis )) oil, kelp, kukui ( kukui) ( aleurites moluc cana )) nut oil, lactamide MEA, laneth-16, laneth-10 acetate, lanolin, lanolin acid, lanolin alcohol, Lanolin oil, lanolin wax, lavender (lavandula angustifolia) oil, lecithin, lemon ( citrus medica limonum ) oil, linoleic acid, linolenic acid , macadamia ternifolia nut oil, maltitol, chamomile (matricaria) ( chamomilla recutita ) oil, methyl glucose sesquistearate, methylsilanol PCA (methylsilanol PCA), mineral oil, mink oil, mortierella oil, myristyl lactate, myristyl myristate, myristyl propionate propionate), neopentyl glycol dicaprylate/dicaprate, octyldodecanol, octyldodecyl myristate, octyldodecyl stearate stearoyl stearate, octyl hydroxystearate, octyl palmitate, octyl salicylate, octyl stearate, oleic acid, olive (oligo) olea europaea ) oil, Orange ( citrus aurantium dulcis ) oil, palm ( elaeis guineensis ) oil, palmitic acid, pantethine, panthenol, panthenyl ethyl ether, paraffin, PCA, peach ( prunus persica ) kernel oil, peanut ( arachis hypogaea ) oil, PEG-8 C12-18 ester, PEG-15 cocamine, PEG-150 distearate, PEG-60 glyceryl isostearate (PEG-60 glyceryl isostearate), PEG-5 glyceryl stearate, PEG-30 glyceryl stearate, PEG-7 hydrogenated castor oil (PEG-7 hydrogenated) castor oil), PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-20 methyl glucose sesquistearate (PEG-20 methyl glucose sesquistearate), PEG40 sorbitan peroleate (PEG40 sorbitan peroleate), PEG-5 soy sterol (PEG-5 soy sterol), PEG-10 soy sterol (PEG-10 soy sterol), PEG-2 stearate (PEG- 2 stearate), PEG-8 stearate, PEG-20 stearate, PEG-32 stearate e), PEG40 stearate, PEG-50 stearate, PEG-100 stearate, PEG-150 stearate, pentadecalactone (pentadecalactone), peppermint ( mentha piperita ) oil, petrolatum, phospholipids, polyamino sugar condensate, polyglyceryl-3 diisostearate 3 diisostearate, polyquaternium-24, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 , polysorbate 85, potassium myristate, potassium palmitate, propylene glycol, propylene glycol dicaprylate/ dicaprate), propylene glycol dioctanoate, propylene glycol dipelargonate, propylene glycol laurate, propylene glycol stearate (propylene) glycol stearate, propylene glycol stearate SE, PVP, pyridoxine dipalmitate, retinol, retinyl palmitate, rice ( Oriza Sativa ( oryza sativa )) bran oil, RNA, rosemary ( rosmarinus officinalis ) oil, rose oil, safflower ( carthamus tinctorius ) oil , sage ( salvia officinalis ) oil, sandalwood ( santalum album ) oil, serine, serum protein, sesame ) ( sesamum indicum ) oil, shea butter (( butyrospermum parkii )), silk powder, sodium chondroitin sulfate, sodium hyaluronic acid (sodium hyaluronate), sodium lactate (sodium lactate), sodium palmitate (sodium palmitate), sodium PCA (sodium PCA), sodium polyglutamate (sodium polyglutamate), soluble collagen (soluble collagen), sorbitan laurate ), sorbitan oleate, sorbitan palmitate, sorbitan sesquioleate, sorbitan stearate, sorbitol, soybean ( glycine soja ) oil, sphingolipids, squalane, squalene, stearamide MEA-stearate, stearic acid, stearoxy dimethicone, Stearoxytrimethylsilane (stear oxytrimethylsilane, stearyl alcohol, stearyl glycyrrhetinate, stearyl heptanoate, stearyl stearate, sunflower (Heliathus Honors) helianthus annuus ) seed oil, sweet almond ( prunus amygdalus dulcis ) oil, synthetic beeswax, tocopherol, tocopheryl acetate, Tocopheryl linoleate, tribehenin, tridecyl neopentanoate, tridecyl stearate, triethanolamine, tristearin, urea (urea), vegetable oil, water, waxes, wheat ( triticum vulgare ) germ oil, and ylang ylang ( cananga odorata ) ) contains oil.

Antioxidants may be used with the composition of the present invention, and non-limiting examples of antioxidants that may be used include acetyl cysteine, ascorbic acid polypeptide, ascorbyl dipalmitate, ascorbyl methylsilanol pectinate, ascorbyl palmitate, ascorbyl stearate, BHA, BHT, t-butyl hydroquinone, Cysteine, cysteine HCI, diamylhydroquinone, di-t-butylhydroquinone, dicetyl thiodipropionate, dioleyl toco Peryl tocopheryl methylsilanol, disodium ascorbyl sulfate, distearyl thiodipropionate, ditridecyl thiodipropionate, dodecyl dodecyl gallate, erythorbic acid, esters of ascorbic acid, ethyl ferulate, ferulic acid, gallic acid esters, hydroquinone ( hydroquinone), isooctyl thioglycolate, kojic acid, magnesium ascorbate, magnesium ascorbyl phosphate, methylsilanol ascorbic acid (meth) ylsilanol ascorbate, natural botanical anti-oxidants such as green tea or grape seed extract, nordihydroguaiaretic acid, octyl gallate, phenylthioglycolic acid (phenylthioglycolic acid), potassium ascorbyl tocopheryl phosphate, potassium sulfite, propyl gallate, quinones, rosmarinic acid, sodium ascorbic acid (sodium) ascorbate), sodium bisulfite, sodium erythorbate, sodium metabisulfite, sodium sulfite, superoxide dismutase, sodium thioglycol Sodium thioglycolate, sorbityl furfural, thiodiglycol, thiodiglycolamide, thiodiglycolic acid, thioglycolic acid, thiolactic acid ( thiolactic acid), thiosalicylic acid, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18 , tocophereth-50, tocopherol, tocophersolan, tocopheryl acetate, tocopheryl linoleate, tocopheryl nicotine tocopheryl nicotinate, tocopheryl succinate, and tris(nonylphenyl)phosphite.

In another non-limiting aspect, the compositions of the present invention may include a structuring agent. In another aspect, the structuring agent helps to provide the rheological characteristics of the composition that contribute to the stability of the composition of the present invention. In another aspect, the structuring agent may also function as an emulsifier or surfactant. Non-limiting examples of structuring agents include stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid acid), palmitic acid, polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, an average of about 1 polyethylene glycol ether of cetyl alcohol having from to about 5 ethylene oxide units, and mixtures thereof.

The composition herein may not contain an emulsifier, but may contain one or more emulsifiers. Emulsifiers can reduce the interfacial tension between phases and can improve the formulation and stability of the emulsion. Emulsifiers can be nonionic, cationic, anionic, and zwitterionic emulsifiers (see McCutcheon's (1986); US Pat. Nos. 5,011,681; 4,421,769; 3,755,560). Non-limiting examples include esters of glycerin, esters of propylene glycol, fatty acid esters of polyethylene glycol, and polypropylene glycol fatty acid esters (fatty acid). esters of polypropylene glycol, esters of sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers, glucose ethers and ethers of glucose, ethoxy Ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, polyethylene fatty ether phosphates, fatty acid amides, acyl lactylates ), soap, TEA stearate, DEA oleth-3 phosphate, polyethylene glycol 20 sorbitan monolaurate (polysorbate 20) (polyethylene glycol 20 sorbitan) monolaurate (polysorbate 20)), polyethylene glycol 5 soya sterol, steareth-2, steareth-20, steareth-21 ), ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, Polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate 60 (polysorbate 60), glyceryl stearate ( glyceryl stearate), PEG-100 stearate (PEG-100 stearate), and mixtures thereof.

In a non-limiting aspect, silicone-containing compounds include any member of the family of polymeric products consisting of alternating silicon and oxygen atoms and side groups attached to silicon atoms in the molecular backbone. do. By varying -Si-O- chain lengths, side groups, and crosslinking, silicones can be synthesized into a wide variety of materials. They can vary in consistency from liquid to gel to solid.

Silicone-containing compounds that may be used in the context of the present invention include those described herein or known to the person of ordinary skill in the art. Non-limiting examples include silicone oils (eg, volatile and non-volatile oils), gels, and solids. In another aspect, the silicone containing compound comprises a silicone oil, such as a polyorganosiloxane. Non-limiting examples of polyorganosiloxane include dimethicone, cyclomethicone, polysilicone-11, phenyl trimethicone, and trimethylsilyl amodimethicone. (trimethylsilylamodimethicone), stearoxytrimethylsilane, or mixtures thereof and other organosiloxane materials for the intended application (eg, a specific area such as skin, hair, or eyes) )) in any given proportion to achieve the desired consistency and application characteristics. “Volatile silicone oil” includes silicone oils that have a low heat of vaporization, ie normally less than about 50 cal per gram of silicone. oil). Non-limiting examples of volatile silicone oils include the following components: Dow Corning 344 Fluid, Dow Corning 345 Fluid, Dow Corning 244 Fluid, and Dow Corning 245 Fluid, Volatile Silicon 7207 (Union Carbide Corp, Danbury) , Conn.) such as cyclomethicones; low viscosity dimethicones, eg ( ie ), dimethicones having a viscosity of about 50 cst or less (eg dimethicones such as Dow Corning 200-0.5 cst Fluid) ). This Dow Corning Fluid is commercially available from Dow Corning Corporation, Midland, Michigan. Cyclomethicone and dimethicone are a mixture of fully methylated linear siloxane polymers end-blocked with trimethylsiloxy units and cyclin dimethyl polysiloxane compounds, respectively. (incorporated by reference) in the third edition. Other non-limiting silicone oils that may be used in the context of the present invention include General Electric Co., Silicone Products Div., Waterford, NY and SWS Silicones Div. of Stauffer Chemical Co., Adrian, Michigan.

Essential oils include oils derived from herbs, flowers, trees and other plants. These oils are usually present as tiny droplets between the cells of the plant and can be prepared by various methods known to those of skill in the art (eg steam distilled, enfleurage). (eg, extraction by using fat), maceration, solvent extraction, or mechanical pressing). When these types of oils are exposed to air they tend to evaporate (eg, volatile oils). As a result, many essential oils are colorless, but with age they can oxidize and darken. Essential oils are insoluble in water and soluble in alcohols, ethers, nonvolatile oils (vegetables), and other organic solvents. Typical physical properties found in essential oils include boiling points varying from about 160° to 240° C. and densities ranging from about 0.759 to about 1.096.

Essential oils are generally named from the plant in which the oil is found. For example, rose oil or peppermint oil was derived from the rose or peppermint plant, respectively. Non-limiting examples of essential oils that may be used in the context of the present invention include sesame oil, macadamia nut oil, tea tree oil, evening primrose oil, spanish oil. Spanish sage oil, Spanish rosemary oil, coriander oil, thyme oil, pimento berries oil, rose oil, anise oil (anise oil), balsam oil (balsam oil), bergamot oil (bergamot oil), rosewood oil (rosewood oil), cedar oil (cedar oil), chamomile oil (chamomile oil), sage oil (sage oil), claire Clary sage oil, clove oil, cypress oil, eucalyptus oil, fennel oil, sea fennel oil, frankincense oil oil), geranium oil, ginger oil, grapefruit oil, jasmine oil, juniper oil, lavender oil, lemon oil ), lemongrass oil, lime oil, mandarin oil, marjoram oil, myrrh oil, neroli oil, orange oil oil), patchouli oil, pepper oil, black pepper oil, petitgrain oil, pine oil oil), rose otto oil, rosemary oil, sandalwood oil, spearmint oil, spikenard oil, vetiver oil, winter green oil (wintergreen oil), or ylang ylang. Other essential oils known to those skilled in the art are also contemplated as useful in the context of the present invention.

The present application may include thickening or gelling agents, thickening agents include substances capable of increasing the viscosity of the composition. Thickeners include those capable of increasing the viscosity of a composition without substantially modifying the effectiveness of the active ingredient in the composition. Thickeners may also increase the stability of the compositions of the present invention. In another aspect of the invention, the thickening agent comprises hydrogenated polyisobutene or trihydroxystearin, or a mixture of the two.

Non-limiting examples of additional thickeners that may be used in the context of the present invention include carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, polysaccharides ( polysaccharides), and gums. An example of a carboxylic acid polymer is one derived from acrylic acid, substituted acrylic acids, and esters and salts of these acrylic acids and substituted acrylic acids. or a crosslinked compound comprising one or more monomers, wherein the crosslinking agent comprises two or more carbon-carbon double bonds and is derived from a polyhydric alcohol (See US Pat. Nos. 5,087,445; 4,509,949; 2,798,053; CTFA International Cosmetic Ingredient Dictionary, 4th Edition, 1991, pages 12 and 80). Examples of commercially available carboxylic acid polymers include carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytritol. ) (eg, Carbopol™ 900 series from BF Goodrich).

Non-limiting examples of crosslinked polyacrylate polymers include cationic and nonionic polymers. Examples are described in US Pat. Nos. 5,100,660; 4,849,484; 4,835,206; 4,628,078; 4,599,379).

Non-limiting examples of polyacrylamide polymers (including nonionic polyacrylamide polymers including substituted branched or unbranched polymers) include polyacrylamide , multi-blocks of isoparaffin and laureth-7, acrylic acids and substituted acrylic acids and acrylamides and substituted acrylamides (multi-block) copolymers.

Non-limiting examples of polysaccharides include cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, and hydroxyethylcellulose. hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate ( sodium cellulose sulfate), and mixtures thereof. Another embodiment is an alkyl substituted cellulose wherein the hydroxy groups of the cellulosic polymer are hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form a hydroxyalkylated cellulose, which is then ether linkage. The branched chain or C ₁₀ -C ₃₀ straight chain of the alkyl group is further modified. Typically, these polymers are hydroxyalkylcelluloses and branched-chain alcohols or C ₁₀ -C ₃₀ straight-chain ethers. Other useful polysaccharides include a linear chain of every 3 units of (1-6) linked glucose and (1-3) linked glucose units ((1-6) linked glucose). It includes a scleroglucan containing.

Non-limiting examples of gums that can be used in the present invention include acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium Calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hide guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydropropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate ), sclerotium gum, sodium carboyxmethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof include

Non-limiting examples of preservatives that may be used in the context of the present invention include polyquaternium-1 and benzalkonium halides (eg, benzalkonium chloride (“BAC”)). and quaternary ammonium preservatives such as benzalkonium bromide), parabens (e.g., methylparabens and propylparabens), phenoxyethanol, benzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal, or a combination thereof.

According to one embodiment of the present application, the cosmetic composition may have the form of a cream formulation. Even if troublesome skin is dry, it may be burdensome to use a cream formulation for sufficient moisturizing. The cosmetic composition of this embodiment can be provided in a creamy, non-sticky, semi-transparent gel-type texture that can sufficiently moisturize even oily skin and sensitive skin.

The cream formulation is from the group consisting of panthenol, sodium hyaluronate, sodium hyaluronate crosspolymer, hydrolyzed hyaluronic acid, hyaluronic acid, and hydrolyzed sodium hyaluronate. It may include a moisturizing agent of choice. Panthenol is a substance excellent in moisturizing and moisture absorption enough to be used as a burn treatment agent, and it can be formulated in the cream formulation of an embodiment to have an excellent moisturizing effect. Hyaluronic acid and its derivatives can have excellent moisturizing power depending on the combination.

According to one embodiment of the present application, the cream formulation may include any one or more oils selected from the group consisting of caprylic/capric triglyceride, ethylhexyl palmitate, and isododecane. Specifically, the content of the caprylic/capric triglyceride may be 1.6 to 2.4% by weight, the ethylhexyl palmitate may include 1.6 to 2.4% by weight, and the isododecane may be included in an amount of 0.8 to 1.2% by weight. By blending with an appropriate amount of oil, a cream formulation having an excellent texture can be prepared.

According to one embodiment of the present application, the cream formulation is selected from acrylate/C10-30 alkyl acrylate crosspolymer, ammonium acryloyldimethyltaurate/VPicopolymer, and glyceryl acrylate/acrylic acid copolymer. It may include any one or more polymers. Specifically, 0.4 to 0.6 wt% of the acrylate/C10-30 alkyl acrylate crosspolymer, 0.4 to 0.6 wt% of the ammonium acryloyldimethyltaurate/vpicopolymer, and the glyceryl acrylate/acrylic acid It may contain 0.16 to 0.24% by weight of the copolymer. By mixing an appropriate amount of polymer, it can have a translucent color and have excellent spreadability.

According to one embodiment of the present application, the cream formulation contains 0.08 to 0.12% by weight of butylene glycol, caprylyl glycol, and pentylene glycol, and 0.008 to 0.012% by weight of arginine, 1, 1.6 to 2.4% by weight of 2-hexanediol, 2.4 to 3.6% by weight of ethylhexylglycerin, 0.4 to 0.6% by weight of polyglyceryl-3 methylglucose distearate, and disodium EDTA and 0.08 to 1.2 wt% of dipotassium glycyrrhizate.

It was confirmed that the cosmetic composition of the present Example has an immediate skin heat soothing effect and an external stimulus soothing effect. In addition, it was confirmed that it was effective in improving the number of pores, area, volume, and depth as well as improving skin redness after 2 weeks. Furthermore, it was confirmed that irritation did not appear when using sensitive skin.

Hereinafter, the configuration of the present invention and its effects will be described in more detail through specific examples and comparative examples. However, these examples are for explaining the present invention in more detail, and the scope of the present invention is not limited to these examples.

Preparation Example 1 - Preparation of yakmomil extract and tea tree extract

3L of purified water is added to 1 kg of each weight of yak buckwheat (domestic) and tea tree (Australia) dried and powdered at 60°C, extracted at about 40°C for 2 days, and then filtered (Whatman NO.5, whatman international Ltd, UK) to prepare an extract. Purified water was added to the extract to prepare an extract of the formulation shown in Table 1 below.

Yamba wheat extract tea tree extract sample 1 20mL (70.0% extract) 20mL (10.0% extract) sample 2 20mL (70.0% extract) - sample 3 - 20mL (10.0% extract) sample 4 20mL (50.0% extract) 20mL (10.0% extract) sample 5 20mL (70.0% extract) 20mL (15.0% extract) Control Purified water

(Unit: % by weight)

Experimental Example 1 - Raw material basic test

(1) Cell culture

The cells used as an example of the present invention were human fibroblast cell line CCD-1064SK (CRL-2076) purchased from ATCC (America Type Culture Collect, USA), mouse macrophage cell line RAW 264.7 (TIB-71), and rat A mast cell line, RBL-2H3 (CRL-2256), was used. The culture medium of CCD-1064SK, RAW 264.7 and RBL-2H3 were respectively IMDM (iscove's modified dulbecco's medium), DMEM (dulbecco's modified eagle's medium) and MEM (minimum essential medium) were purchased from Gibco (USA) and used, respectively. FBS (fetal bovine serum, Gibco, USA) (10% FBS for CCD-1064SK, RAW 264.7, 15% FBS for RBL-2H3) and 1% antibiotic-antimycotic solution (Giboco, USA) were added to the medium. and used for cell culture. All cells were cultured in a cell incubator (ELITE II, Revco, USA) at 37° C. and 5% CO 2 conditions, and the experiment was performed.

(2) measurement of cytotoxicity

In order to measure the cytotoxicity of the sample extracts prepared by Preparation Example 1, MTT (thiazolyl blue tetrazolium bromide, Sigma, USA) method ( J. Immunol. Methods , 141(1), 15 (1991)) was used. It proceeded as follows. The MTT method is a method used to measure cell proliferation or toxicity. The principle of reduction of MTT, a yellow water-soluble salt, to insoluble purple MTT formazan by succinate dehydrogenase in mitochondria of living cells. method used.

CCK-1064SK fibroblasts cultured by the method of (1) above were inoculated ^{into a 24-well plate (Nunc, USA) at a density of 1×10 5} cells/well, cultured for 1 day, and replaced with serum-free IMDM, and the sample The final concentrations of the extracts were 1, 5, and 10 μg/ml, respectively.　It was added to the concentration and incubated for 24 hours. MTT solution prepared at a concentration of 2.5 mg/ml was added at 0.1 ml/well, and after reaction at 37° C. for 4 hours, the MTT solution was removed, and DMSO (dimethylsufoxid) was added at 0.5 ml/well. After dissolving MTT formazan at room temperature, absorbance was measured at 570 nm, and the difference in absorbance with the negative control group was compared, and the results are shown in Table 2.

sample Concentration (μg/mL) cell viability Control - 100.00 ±2.77 sample 1 One 99.64 ±1.98 5 98.32 ±2.13 10 101.54 ±1.98 sample 2 One 100.54 ±2.19 5 97.94 ±1.08 10 102.34 ±2.91 sample 3 One 101.43 ±1.95 5 99.34 ±1.48 10 97.45 ±2.04 sample 4 One 99.40 ±2.01 5 103.29 ±2.18 10 97.30 ±2.03 sample 5 One 84.20±1.25 5 75.30±1.25 10 53.59 ±4.29

(3) iNOS (inducible nitric oxide synthase) production inhibitory effect

RAW 264.7 cultured in (1) above ^{was inoculated in a 24 well plate at a density of 8 × 10 5} cells/well and cultured for 1 day, followed by inflammatory reaction-inducing substance LPS (lipopolysaccharide from E.coli, Sigma, USA) was replaced with phenol-red free DMEM containing 0.1 μg/ml, and the sample extracts were added by concentration and cultured for 1 day. After that, 100 μl of the culture medium and 100 μl of Griess' reagent (Fluka, USA) were mixed, absorbance at 570 nm was measured, and the absorbance was compared with the LPS-positive control group to analyze the effect of inhibiting the iNOS activity induced by LPS. It is shown in Figure 3. (The color of the Griess' reagent changes according to the concentration of NO, so it acts as an indicator.)

sample Concentration (μg/mL) iNOS activity (% of LPS) Control - 35.91 ±2.84 LPS 0.1 100.00 ±1.97 sample 1 One 59.43 ±1.52 5 40.31 ±2.40 10 27.92 ±3.71 sample 2 One 91.09 ±1.04 5 80.58 ±2.27 10 65.78 ±1.92 sample 3 One 98.26 ±4.16 5 94.63 ±3.74 10 91.94 ±1.92 sample 4 One 80.25 ±3.93 5 75.24 ±3.11 10 69.84 ±1.98 sample 5 One 69.21±4.18 5 45.18±3.17 10 31.21 ±4.01

Looking at the results in Table 3, the iNOS activity inhibitory effect in Sample 1 was found to have a sedative effect. This was confirmed to be significantly better than samples 2 and 3 including only one extract. The synergistic effect of the two extracts was confirmed as Sample 2, which contained a large amount of buckwheat extract, contained less of the extract, and had a lower inflammation-inducing inhibitory effect than Sample 4 to which the tea tree extract was added. Sample 5, in which a large amount of tea tree extract was added, did not appear to have a higher effect than sample 1, so it was found that the tea tree extract did not show cytotoxicity and had an optimal ratio to increase the soothing effect. (4) For human skin Primary stimulus check test

The presence or absence of primary stimulation of the active ingredients of Samples 1 to 5 on human skin was measured according to the PCPC guidelines (2014).

Subjects who met the selection criteria and did not meet the exclusion criteria were selected for more than 30 healthy men and women aged 20 to 60 years without skin disease. Those who showed their intention to participate by explaining the purpose, method, and adverse reaction of the test to the selected subjects were asked to fill out a consent form to participate in the test and participate in the test.

This study was conducted on over 30 women aged 20 to 60 who met the criteria for subject selection and did not meet the exclusion criteria through examination of the subject's background and medical history. The test site was washed with 70% ethanol and dried. After applying 20ul of each of the samples to the back for 24 hours, the first evaluation was performed 20 minutes after the patch was removed, and the second evaluation was performed after 24 hours.

The skin primary stimulus response was evaluated according to the PCPC Guidelines as shown in Table 4 (Table 4).

ranking Description of clinical findings +1 Slight erythema +2 Moderate erythema, possibly with barely perceptible edema at the margin, papules may be present +3 Moderate erythema, with generalized edema +4 Severe erythema with severe edema, with or without vesicles +5 Severe reaction spread beyond the area of the patch

The average reactivity was calculated according to the following formula for the skin reaction results for the samples. The average reactivity of the calculated samples was determined as follows. However, in the PCPC Guidelines, a skin reaction with grade +5 is clinically more likely to be an allergic reaction rather than an irritant response.

Range of response Judgment 0.00 ≤ R < 0.87 None to Slight 0.87 ≤ R < 2.42 Mild 2.42 ≤ R < 3.44 Moderate 3.44 ≤ R Severe

A total of 30 people participated in the whole process of the test. The average age of the subjects was 42.53±7.74 years, the highest age was 50 years, and the lowest age was 20 years. The skin information of the subjects was investigated by questionnaire.

number of responders 20 minutes 24 hours +1 +2 +3 +4 +1 +2 +3 +4 sample 1 2 2 sample 2 4 One 2 One sample 3 3 One 2 sample 4 2 2 sample 5 3 One 2

In terms of human skin primary irritation, samples 2 and 5 were considered mild, and the rest were considered hypoallergenic.

Preparation Example 2 - Preparation of cream formulation

A cream formulation was prepared according to the composition of Table 7. The formulation may be prepared by mixing the ingredients in a beaker at a temperature of 70-75° C. until homogenous. The formulation may then be cooled to standing room temperature (20-25° C.).

Example 1 Yamba wheat extract 0.1 (71.8% extract) tea tree extract 0.1 (9.7% extract) glycerin 6.0 Butylene Glycol 0.1 caprylyl glycol 0.1 pentylene glycol 0.1 panthenol 0.03 Arginine 0.01 1,2-Hexanediol 2.0 Purified water Remainder Caprylic/Capric Triglycerides 2.0 Ethylhexyl Palmitate 2.0 isododecane 1.0 Ethylhexylglycerin 3.0 Acrylate/C10-30 alkyl acrylate crosspolymer 0.5 Ammonium acryloyldimethyl taurate/vpicopolymer 0.5 Glyceryl Acrylate/Acrylic Acid Copolymer 0.2 Polyglyceryl-3 methylglucose distearate 0.5 Disodium EDIT 0.1 dipotassium glycyrrhizate 0.1 Sodium Hyaluronate 0.01 Sodium hyaluronate crosspolymer 0.01 Hydrolyzed Hyaluronic Acid 0.01 hyaluronic acid 0.01 Hydrolyzed Sodium Hyaluronate 0.01

It was confirmed that the cosmetic composition of the cream formulation of Example 1 had a non-sticky, translucent gel-type texture. On the other hand, Comparative Example 1 was prepared using 85.0% (w/w), tea tree extract, and 9.7% (w/w), yakmomil extract in Example 1, 71.8% (w/w), tea tree extract, yakmomil extract. Comparative Example 2 using 12.0% (w/w) was prepared. In the case of Comparative Example 1, it was not selected as the final formulation because it had some stickiness, and in the case of Comparative Example 2, it was not selected due to poor transparency.

Experimental Example 3 - Primary skin irritation test

The cream formulation of Example 1 was implemented to check whether or not there was a primary irritation to the human skin of a sensitive skin target.

Criteria for selection of test subjects

Thirty-three adults aged 20 to 55 who met the following selection criteria were recruited:

1. Adults between 20 and 55 years of age

2. Those who have been judged to have sensitive skin by a breast cut test

3. Those who do not have acute or chronic diseases including skin diseases

4. A person who voluntarily signed the consent form after hearing the explanation about the purpose and content of the test

5. Those who can follow up during the test period

Those who met the following criteria were excluded from the study:

1. If you do not want to or if you do not fill out the consent form

2. If it is difficult to evaluate the evaluation site due to trauma such as erythema, crusting, abrasions, tattoos, scars, etc.

3. If you have an infectious skin disease

4. If you have a history of skin reaction or drug treatment

5. If you have severe irritation or allergies to cosmetics, pharmaceuticals, or daily exposure to light

6. In case of participating in other human application tests

7. If you are pregnant or lactating

8. In addition to the above, if it is judged that it is difficult to conduct a human application test by the judgment of the responsible researcher or the person in charge of the study.

Test Methods

1. Patch area: A flat area on the back of the test subject except for the spine, and there is no pigmentation or skin damage.

2. Evaluation items

1) Visual evaluation of the researcher

- How to evaluate the degree of skin irritation:

Based on the Frosch & Kligman, CTFA guideline, read the skin reactivity and check the range of skin irritation index applying the Draize method to classify the level of skin irritation

3. Other investigation (observation) items

1) Demographic Survey: Survey of gender, date of birth, and age before starting the human application test

2) Health Status Investigation: Visual inspection to check whether it is suitable for human application testing

3) Medical history: Investigate the main symptoms, onset date, examination and treatment history before starting the human application test

4. Visit schedule: 3 visits

1) Visit 1: Subject consent, subject selection test, test product patching, adverse reaction confirmation

2) Visit 2: Patch removal, visual evaluation of skin reaction 1 hour after patch removal, confirmation of adverse reactions

3) Visit 3: Visual evaluation of skin reaction 24 hours after patch removal, confirmation of adverse reactions

Test result

Thirty-three subjects who completed this study were 10 males and 23 females, with an average age of 35.576 years. The skin conditions of the test subjects were dry skin 10 people, medium dry skin 6 people, neutral skin 12 people, oily skin 3 people, oily skin 2 people. There was no history of disease or drug use.

test product degree of skin irritation test substance Example 1 Non (non-irritating) Substances that cause cut sensation SLS 0.1% mild irritant SLS 0.3% mild irritant D.W. Non (non-irritating)

As a result of the researcher's visual evaluation of the skin reaction 1 hour and 24 hours after removal of the patch, Example 1 was judged to be non-irritating.

Experimental Example 4 - Skin soothing and pore convergence human application test

For the cream formulation of Example 1, it was carried out to evaluate the effects of skin soothing, skin heat soothing (cooling), skin irritation caused by (physical) external stimulation, and improving the number of pores, pore area, pore volume, and pore depth.

Selection of test subjects

Adult females aged 20 to 59 who satisfy the criteria for selection and exclusion of subjects

Those who meet the following selection criteria

1. Those with redness on their face

2. A person who voluntarily wrote and signed the consent form after fully explaining the matters to be informed to the subject from the principal investigator or a person delegated by the principal investigator

3. A healthy person without acute or chronic physical disease including infectious skin disease

4. Those who can follow-up during the test period

Those who met the following criteria were excluded from the study:

1. Pregnant or lactating women and women of childbearing potential

2. If you do not want to or if you do not fill out the consent form

3. If you have a psychiatric illness

4. In case of receiving immunosuppressant treatment within 3 months of participation in the trial

5. If you have received systemic steroids or phototherapy within 1 month of participating in the trial

6. In case there is a lesion in the test site and measurement is difficult

7. If you have atopic skin

8. If you have a severe reaction or allergy to cosmetics, pharmaceuticals, or routine light exposure

9. If you have received skin scaling or skin care within 3 months of participating in the test

10. Other than the above, if it is judged that it is difficult to conduct a human test by the responsible researcher or the person in charge of the study

Test Methods

1. Evaluation items

1) Instrumental evaluation

- Skin soothing measurement (Visia-CR → Image-proR plus)

- Measurement of skin thermal soothing (cooling) (thermal imaging camera (T-530))

- Measurement of soothing skin irritation caused by (physical) external stimulation (Antera 3D CS)

- Pore count/area/volume/depth measurement (Antera 3D CS)

2) Global Assessment of Efficacy

- Subject evaluation

3) Safety evaluation

At each visit, the researcher evaluates the results of the researcher's visual evaluation of the site where the test product is used and the results of the subject's questionnaire.

2. Other investigation (observation) items

1) Demographic Survey: Survey of gender, date of birth, and age before starting the human application test

2) Health Status Investigation: Visual inspection to check whether it is suitable for human application testing

3) Medical history investigation: Investigation of the main symptoms, onset date, examination and treatment history before the start of the human application test

4) Product preference survey: Investigate product preference through questionnaire data

3. Visit schedule: 4 visits

1) Visit 1: Subject consent, subject selection test, screening even number test

Measurement of skin soothing before using the test product, measurement of the number/area/volume/depth of pores before and immediately after using the test product, confirmation of adverse reactions, distribution of the test product

2) Visit 2: Screening odd-numbered test subjects before using the test product, measuring skin soothing, measuring the number/area/volume/depth of pores before and immediately after using the test product, checking for adverse reactions, and distributing test products

3) Visit 3: Before infrared irradiation, after infrared irradiation, immediately after using the test product, measure skin heat soothing (cooling), check for adverse reactions

4) Visit 4: Skin soothing after 2 weeks of using the test product, measuring the number/area/volume/depth of pores, before TS (Tape stripping), after TS, after 30 minutes of using the test product, soothing skin irritation caused by (physical) external stimulation Measurement, confirmation of adverse reactions, recall of test products, questionnaire evaluation

Test result

1) All 22 test subjects (without dropout: 1) who completed this study were all female, and the average age was 41.409 years old. The selected subjects did not have any specific skin symptoms and had no history of diseases or medications that could affect the study.

2) As a result of confirming the change in skin redness (a*) to check for skin soothing after using the test product, it significantly decreased (p<0.05) after 2 weeks of use compared to before use.

3) As a result of checking the change in skin temperature (°C) to check for skin thermal soothing (cooling) after using the test product, both the site where the test product was used and the non-applied area increased significantly after infrared irradiation compared to before infrared irradiation (p <0.05), and significantly decreased (p<0.05) immediately after use compared to after infrared irradiation.

In addition, there was a significant difference (p<0.05) immediately after the use of the test product compared to the non-applied site after infrared irradiation.

4) After using the test product, the change in skin redness (a*) was checked to check for soothing skin irritation caused by (physical) external stimuli. It increased significantly (p<0.05) after TS, and decreased significantly (p<0.05) after 30 minutes of use compared to after TS.

In addition, there was a significant difference (p<0.05) in the site where the test product was used 30 minutes after TS compared to the non-applied site.

5) As a result of checking the change in the number/area/volume/depth of pores after using the test product,

- Number: There was a significant decrease (p<0.05) immediately after use and 2 weeks after use compared to before use.

- Area: significantly decreased (p<0.05) immediately after use and 2 weeks after use compared to before use.

- Volume: significantly decreased (p<0.05) immediately after use and 2 weeks after use compared to before use.

- Depth: Compared with before use, it decreased significantly (p<0.025) immediately after use and 2 weeks after use.

6) Efficacy evaluation survey results for test products, skin soothing effect, skin heat soothing (cooling) effect, skin irritation soothing effect due to (physical) external stimuli, pore convergence (pore count/area/volume/depth) effect items 100.000% of the test subjects rated it as above average.

7) There were no reports of any special skin adverse reactions during the period the subject used the test product, and no abnormal findings were observed on physical examination by a dermatologist.

Therefore, the cream formulation of Example 1 is judged to be a product that helps to soothe skin heat (cooling), soothe skin irritation caused by (physical) external stimulation, and improve the number of pores, pore area, pore volume, and pore depth with one use . The cream formulation of Example 1 is judged to be a product that helps improve skin soothing, number of pores, pore area, pore volume, and pore depth after 2 weeks of use. The cream formulation of Example 1 is judged to be a product that helps the pore astringent effect by using it once and for 2 weeks.

Claims (3)

A cosmetic composition for soothing the skin comprising, as an active ingredient, a herbal extract and a tea tree extract, wherein the herbal extract has a concentration of 60 to 80% (w/w), and the tea tree extract is 8.0 to 12.0% (w/w) w), wherein the yakmomil extract and the tea tree extract have a weight ratio of 1: 0.8 to 1.2, as a cosmetic composition for skin soothing,
The cosmetic compositions and of the type of the cream formulation,
The cream formulation is from the group consisting of panthenol, sodium hyaluronate, sodium hyaluronate crosspolymer, hydrolyzed hyaluronic acid, hyaluronic acid, and hydrolyzed sodium hyaluronate. a moisturizing agent of choice;
containing at least one oil selected from the group consisting of caprylic/capric triglyceride, ethylhexyl palmitate, and isododecane;
It contains any one or more polymers selected from acrylate/C10-30 alkyl acrylate crosspolymer, ammonium acryloyldimethyltaurate/vpicopolymer, and glyceryl acrylate/acrylic acid copolymer,
The cosmetic composition contains 0.08 to 0.12% by weight of the yakmomil extract, 0.08 to 0.12% by weight of the tea tree extract, 0.024 to 0.036% by weight of the panthenol, and 1.6 to 1.6% by weight of the caprylic/capric triglyceride 2.4 wt%, 1.6 to 2.4 wt% of the ethylhexyl palmitate, 0.8 to 1.2 wt% of isododecane, 0.4 to 0.6 wt% of the acrylate/C10-30 alkyl acrylate crosspolymer, the ammonium Acryloyldimethyl taurate/vpicopolymer in an amount of 0.4 to 0.6% by weight, and the glyceryl acrylate/acrylic acid copolymer in an amount of 0.16 to 0.24% by weight,
The cosmetic composition comprises 0.08 to 0.12 wt% of butylene glycol, caprylyl glycol, and pentylene glycol, 0.008 to 0.012 wt% of arginine, and 1.6 to 1,2-hexanediol 2.4% by weight, including 2.4 to 3.6% by weight of ethylhexylglycerin, 0.4 to 0.6% by weight of polyglyceryl-3 methylglucose distearate, disodium EDTA and dipotassium glycyrrhizate 0.08 to 1.2% by weight, the skin soothing cosmetic composition.
delete delete